Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.
Ligand Pharmaceuticals Inc. will spin off its antibody discovery business into a new entity known as OmniAb Inc., which will then merge with special-purpose acquisitions company Avista Capital Partners and head to the Nasdaq Stock Market.
GlaxoSmithKline’s consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever.
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech Inc. launched subsidiary Jeune Inc. to promote gene therapies for aesthetic skin conditions.
